Login / Signup

Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.

Minji SohnSeoungyeon NamMichael A NauckSoo Lim
Published in: BMC medicine (2024)
SGLT2is were superior for preserving renal function and reducing body weight, whereas GLP1RAs were better for managing glucose dysregulation and dyslipidaemia.
Keyphrases
  • body weight
  • type diabetes
  • glycemic control
  • blood glucose
  • cardiovascular disease
  • insulin resistance
  • blood pressure
  • skeletal muscle
  • bone marrow
  • weight loss
  • replacement therapy